JANX Janux Therapeutics, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1817713 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY132.9%
TTM net income YoY2.0%
TTM EPS YoY4.8%
Revenue 3-yr CAGR40.1%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-599.3%
Net margin-428.7%
FCF margin-232.6%
EBITDA margin-591.3%
Returns
ROE-10.6%
ROA-9.9%
ROIC (approx.)-12.3%
Asset turnover0.02x
Leverage & solvency
Liabilities / assets7.3%
Debt / equity0.00x
Current ratio17.69x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.54x
Accruals ratio-4.6%
Payout ratio—
Capex / revenue2.5%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $10.00M | $10.59M | $8.08M | $8.61M | $3.64M |
| R&D expense | $125.90M | $68.39M | $54.92M | $53.44M | $26.24M |
| SG&A expense | $41.77M | $41.05M | $26.14M | $22.26M | $10.33M |
| Operating income | -$157.67M | -$98.85M | -$72.98M | -$67.09M | -$32.93M |
| Income tax | $0 | $0 | $0 | — | — |
| Net income | -$113.62M | -$68.99M | -$58.29M | -$63.06M | -$32.67M |
| EBITDA | -$155.64M | -$96.79M | -$71.02M | -$66.25M | -$32.82M |
| EPS (basic) | -1.83 | -1.28 | -1.32 | -1.52 | -1.39 |
| EPS (diluted) | -1.83 | -1.28 | -1.32 | -1.52 | -1.39 |
| Weighted avg. shares (diluted) | 61.97M | 53.75M | 44.02M | 41.47M | 23.53M |
| Balance sheet | |||||
| Cash & equivalents | $52.33M | $430.61M | $19.20M | $51.43M | $35.58M |
| Short-term investments | $914.23M | $594.57M | $324.82M | $275.59M | $339.38M |
| Receivables | $0 | — | $0 | $0 | $0 |
| Current assets | $975.89M | $1.03B | $349.24M | $332.44M | $377.02M |
| PP&E, net | $3.85M | $4.86M | $7.00M | $7.09M | $1.41M |
| Total assets | $1.00B | $1.06B | $380.41M | $364.01M | $379.82M |
| Current liabilities | $25.00M | $17.46M | $13.03M | $16.51M | $12.80M |
| Total liabilities | $44.74M | $38.73M | $36.06M | $43.27M | $13.50M |
| Shareholders' equity | $956.82M | $1.02B | $344.35M | $320.74M | $366.33M |
| Shares outstanding | 60.38M | 59.06M | 46.25M | 41.62M | 41.24M |
| Cash flow statement | |||||
| Operating cash flow | -$82.23M | -$43.81M | -$50.58M | -$42.92M | -$16.98M |
| Capital expenditure | $1.04M | $359,000 | $1.85M | $6.45M | $1.48M |
| Free cash flow | -$83.28M | -$44.17M | -$52.42M | -$49.37M | -$18.46M |
| Investing cash flow | -$300.98M | -$258.02M | -$41.19M | $58.27M | -$340.96M |
| Financing cash flow | $4.95M | $713.24M | $59.55M | $500,000 | $386.52M |
| Depreciation & amortization | $2.03M | $2.06M | $1.96M | $841,000 | $113,000 |
| Stock-based compensation | $40.22M | $33.02M | $20.00M | $17.20M | $6.91M |
Free plan shows the latest 5 periods; Pro shows all 6 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.